For Group 4 patients (CTLA-4high tumor cells, densitylow CTLA-4+ lymphocytes), CTLA-4 blockade alone would not induce an effective anti-tumor immunity given the paucity of preexisting TILs; combination therapies aimed at eliciting anti-tumor immunity are needed. Here, CTLA4 is linked to neoplasm.